Lynx.MD Partners Showcase Groundbreaking Research at ARS 2024 Symposium

Research

Lynx.MD Partners Showcase Groundbreaking Research at ARS 2024 Symposium

Descriptive Analysis of CRSwNP Patients in US Clinical Practice Presented at the American Rhinologic Society Annual Meeting

Lynx.MD is proud to have supported our partners, Sanofi and Regeneron, in the successful presentation of a new study at the American Rhinologic Society (ARS) 70th Annual Meeting in September 2024. The study provided valuable insights into the characteristics of chronic rhinosinusitis with nasal polyps (CRSwNP) patients in the US healthcare system. The research was conducted using the Lynx.MD platform and real-world data from prominent otolaryngology practices, analyzing patient demographics, clinical features, and treatment patterns.

Poster Session Summary: The poster, titled “A Descriptive Analysis of Characteristics of CRSwNP Patients within US Clinical Practice,” was presented during the ARS 2024 Symposium at the Fontainebleau Miami Beach on September 27-28, 2024. It detailed the outcomes of a retrospective longitudinal study aimed at understanding the real-world characteristics of CRSwNP patients, particularly whether they underwent surgery after diagnosis.

Key Study Findings: The study analyzed data from 6,219 CRSwNP patients diagnosed between July 2018 and December 2022. Researchers categorized patients into surgical and non-surgical groups, finding that:

28% (1,726 patients) underwent surgery.
Surgical patients were younger, with an average age of 47.4 years, compared to the non-surgical group, whose average age was 51.5 years.
Those who underwent surgery had a higher prevalence of comorbidities such as atopy, allergic rhinitis, and asthma.
Surgical patients showed greater use of biologic medications (15.5% vs. 11.7%) and began these treatments earlier (426.7 days vs. 498.5 days).
Oral corticosteroid use was significantly higher among surgical patients (82.9% vs. 57.5%).

Conclusion: The study highlighted distinct differences between surgical and non-surgical CRSwNP patients in the US, with surgical patients tending to be younger and having more complex clinical profiles. This underscores the importance of personalized treatment approaches in managing CRSwNP.

Looking Forward: Lynx.MD is proud to have contributed to this important research by providing access to real-world data and facilitating meaningful insights that can drive better patient outcomes. The results shared at ARS 2024 mark a significant step forward in understanding CRSwNP patient profiles and treatment patterns in the US.

Click to Enlarge

Platform

Sanofi

Lynx.MD Trusted Data Environment Research Platform

Regeneron

Authors

Joseph K. Han, Eastern Virginia Medical School, Shahar Rosenberg, Lynx.MD, Rachel Black AESARA, Inc., Richard Stanford AESARA, Inc., Aakash Gandhi, Sanofi, Nita Thingalaya, Sanofi, Ofir Sagi, Lynx.MD, Mark Corbett, Sanofi, Scott Nash, Regeneron, Hernan Avella, Sanofi, Arun Subramaniam, Sanofi

Explore More with Lynx.MD

If you’re ready to harness the power of real-world data for innovative research and actionable insights, Lynx.MD is here to help. Leverage our extensive data resources, data science expertise, and the AI-driven Lynx.MD platform to unlock new possibilities in healthcare research.

Request Demo

Revolutionize IBD Treatment Through Real-World Data

Research

Lynx.MD Collaboration with Prometheus Labs to Revolutionize IBD Treatment

Innovative Research for Inflammatory Bowel Disease

Lynx.MD played a critical role in publishing and accepting four industry abstracts for Prometheus Laboratories, through collaboration and the Lynx.MD platform, Prometheus was able to harness de-identified real-world clinical data from Gastro Health to compare inflammatory bowel disease (IBD) surgeries and related expenditures between infliximab dose-optimized patients using therapeutic drug monitoring (TDM) versus a no TDM control group. These comprehensive studies, conducted with real-world data from Gastro Health’s community-based gastroenterology practices, resulted in the submission and poster presentation of four abstracts at major conferences.

Results

4 Published Abstracts

Crohn’s and Colitis Conference

2024

DDW

2024

ISPOR

2024

AMCP

2024

3x Faster Research to Results

Innovative Research for Inflammatory Bowel Disease

Lynx.MD bridges the gap between healthcare providers, medtech, and life sciences companies by providing quick access to real-time, real-world clinical data in a secure environment. Gastro Health, one of the largest regional gastroenterology practices in the country, played a crucial role in supplying data for this groundbreaking research. Working alongside Lynx.MD’s research analytics team, Prometheus Laboratories contributed to the formulation of meaningful research hypotheses, thorough data exploration, and the creation of the final poster submissions.

Efficient and Secure Data Handling

All research was efficiently managed within the Lynx.MD platform, which handled both structured and unstructured data. The data was de-identified and securely stored within the platform, enabling faster access to results. Remarkably, the Lynx.MD platform demonstrated a threefold increase in speed from data collection to abstract submission compared to traditional real-world data methodologies.

Lynx.MD Solution

Through this collaborative effort, Prometheus Labs is pioneering the future of IBD treatment, driving advancements that promise to benefit patients, healthcare providers, and the broader medical community.

Data Aggregation:

Lynx.MD united a decade’s worth of de-identified clinical and patient data related to IBD. This extensive dataset provides invaluable insights into patterns, trends, and effective treatments.

Research:

Leveraging real-world data, Lynx.MD investigated and highlighted the value of the Prometheus Anser® IFX therapeutic drug monitoring test. This research will identify more effective treatment strategies based on actual patient data.

Outcome Enhancement

The collaboration’s insights aim to enhance patient clinical outcomes, improving the quality of life for IBD patients. This initiative potentially reduces hospital stays, complications, and other costly interventions, thereby alleviating the strain on the healthcare system.

Economic Impact:

Optimizing treatments and improving patient outcomes can significantly reduce overall healthcare costs associated with IBD for patients, providers and payers.

Want to see how it works?

Request Demo

Crohn’s Colitis Congress 2024 Poster Presentation

Research

Lynx.MD Proudly Supports Prometheus Lab’s Crohn’s Colitis Congress 2024 Poster Presentation

Lynx.MD is honored to be a part of Prometheus Lab’s research presented at the Crohn’s & Colitis Congress in January 2024. The study, led by presenter Andrew Shim, delves into the realm of therapeutic monitoring and its impact on real-world outcomes in the treatment of Inflammatory Bowel Disease (IBD).

Click to Enlarge

Comparing Real-World Outcomes, Measured as 12 And 24-Month IBD-Related Surgeries, Between Infliximab Dose Optimized Patients Using Therapeutic Drug Monitoring (TDM) Vs An Unoptimized Control Group, In A Large US Community-Based Gastroenterology Practices. Presented at Crohn’s & Colitis Congress, January 2024.

Download the Poster

Platform

Prometheus Labs

Lynx.MD Trusted Data Environment Research Platform

Gastro Health Longitudinal Patient Data Source

Strategic Differentiation

Prometheus Laboratories worked in partnership with the Lynx.MD data science team to define and analyze the data.

With the Lyxn.MD Trusted Data Environment the longitudinal patient data remained in Gastro Health’s secure cloud environment. All data was anonymised prior to study.

The Lynx.MD platform provided statistical insights on the fly and tailored specific filtering functionality – which enhanced the speed to value approach for Prometheus research team in fine tuning protocol details.

Contributors

Andrew Shim, Presenter, Medical Affairs, Prometheus Laboratories Inc, San Diego, CA, University of Minnesota, Minneapolis, MN
Patita Han, Research & Development, Prometheus Laboratories Inc, San Diego, CA
Kendra Young, University of Minnesota, Minneapolis, MN
Samantha St. Jacque, University of Minnesota, Minneapolis, MN, Prometheus Laboratories, San Diego, CA
Amit Sabban, Data Analytics, Lynx.MD, Ramat Gan, Israel
Dr. Robert Eisdorfer, Chief Medical Officer, Lynx.MD, Ramat Gan, Israel
Shahar Rosenberg, Data Science and Analytics, Lynx.MD, Ramat Gan, Israel
Gastro Health, Data Partners, Miami, FL

Abstract

The study examines the impact of therapeutic drug monitoring (TDM) with Anser® on optimizing Infliximab (IFX) therapy for moderate-to-severe IBD in a community-based gastroenterology setting. It aims to compare real-world outcomes, including IBD-related surgeries, between IFX dose-optimized patients using Anser® TDM and an unoptimized control group.

Methods 
De-identified patient charts from Gastro Health, a US-based community gastroenterology practice, treated with IFX from 2016 to 2022, were analyzed. The Anser TDM cohort and no TDM control group were matched by propensity score, baseline disease, demographics, and comorbidities. Real-world outcomes were accessible via the Lynx.MD secure cloud-based data environment, with statistical analysis conducted by Lynx.MD.

Results 
The Anser TDM group demonstrated significantly lower rates of IBD surgeries at both 12 and 24 months compared to the no TDM group. For all IFX patients at 12 months, rates were 1.2% vs. 6.5% (P=0.001), and at 24 months, 4.1% vs. 9.8% (P=0.016). Similar trends were observed in TNF-N patients.

Conclusions 
This analysis provides crucial insights demonstrating that the Anser IFX TDM group exhibited significantly lower rates of IBD surgeries compared to a matched cohort of no TDM patients in the same community gastroenterology clinic setting.

Want to see how it works?

Request Demo